Tebentafusp-Tebn (Kimmtrak®) for HLA-A*02:01-Positive Unresectable or Metastatic Uveal Melanoma

    March 2022 in “ Oncology Times ”
    Rachel Mehringer
    Studysummary In this study, tebentafusp-tebn improved overall survival in patients with metastatic uveal melanoma compared to standard therapies, despite higher rates of significant adverse events.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on journals.lww.com →
    Discuss this study in the Community →